Avaliação dos Efeitos do Campo Eletromagnético Pulsado na Osteoartrite Inflamatória do Joelho
Estudo Piloto Controlado, Randomizado e Duplamente Cego para Avaliar o Efeito do Campo Electromagnético Pulsado na Osteoartrite Inflamatória do Joelho
This study will assess the efficacy of pulsed electromagnetic field therapy in patients with inflammatory knee osteoarthritis confirmed by MRI-detected effusion-synovitis. Fifty participants will be randomly allocated into two groups. One group will receive active PEMF therapy at a specific optimized parameter twice a week for 8 weeks, while the other group will receive sham treatment using the same device without PEMF signal. The primary outcome is the change in WOMAC pain score, and secondary outcomes include knee function, stiffness, quality of life, and MRI-quantified structural changes.
Visão geral do estudo
Status
Condições
Descrição detalhada
Knee osteoarthritis (KOA) is a leading cause of pain and disability, posing a significant socioeconomic burden. Current treatments often focus on pain relief with safety concerns, and no disease-modifying drugs are available. Pulsed electromagnetic field (PEMF) therapy is a non-invasive and safe physical modality with potential anti-inflammatory and analgesic effects. However, existing evidence for its efficacy in KOA is inconsistent, likely because KOA is a heterogeneous disease, and previous studies have not targeted specific subtypes. The inflammatory KOA subtype, identifiable via MRI, is the most prevalent and represents a critical target for precise intervention.
Methods This study is a double-blind, randomized, placebo-controlled pilot trial. Fifty patients with inflammatory KOA, confirmed by the presence of effusion-synovitis on MRI will be recruited. Participants will be randomly assigned to receive either active PEMF therapy at a specific, optimized parameter or sham treatment twice a week for 8 weeks. The primary outcome is the change in the WOMAC pain score at 3 months after treatment. Secondary outcomes include knee function and stiffness (WOMAC), quality of life (SF-12), and quantitatively assessed structural changes on MRI (e.g., effusion synovitis volume).
Expected Results The investigators anticipate that the group receiving active PEMF therapy will show a statistically significant and clinically important greater reduction in WOMAC pain scores compared to the sham treatment group.The investigators also expect to observe improvements in secondary outcomes, including better knee function and reduced signs of inflammation on MRI in the treatment group.
Conclusion This will be the first clinical trial to evaluate PEMF therapy specifically for the inflammatory subtype of KOA. Positive findings will provide crucial evidence for a novel, non-invasive, and precise therapeutic strategy for KOA management. This has the potential to improve patient care, alleviate the disease burden, and reduce healthcare costs.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Ye LI
- Número de telefone: +85227664842
- E-mail: ye-julie.li@polyu.edu.hk
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Knee visual analogue scale (VAS) pain of <40 mm (0-100 mm)
- Effusion-synovitis or Hoffa synovitis MRI semi-quantitative score of ≥2 (used to determine inflammatory subtype KOA);
- Kellgren-Lawrence (KL) grade II and III
- Patients can listen, speak, read, and understand Chinese; understand the pilot study's requirements and are willing to cooperate with the investigator in conducting the pilot study
- Willing and able to provide written informed consent
Exclusion Criteria:
- Other inflammatory arthritis (e.g., gout, reactive arthritis, rheumatoid arthritis, psoriatic arthritis, and seronegative spondyloarthropathy) and systemic lupus erythematosus.
- Participants with usual KOA interventions/ treatments
- History of knee trauma
- Contraindications to MRI
- Administration of intra-articular, intramuscular, and oral glucocorticoids within the last 4
- Pregnancy and lactation
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: PEMF Therapy Intervention Patients with inflammatory KOA receive active PEMF therapy with optimized
Active Pulsed Electromagnetic Field (PEMF) Therapy Active PEMF therapy at specific optimized parameters, administered twice a week for 8 weeks |
Assigned Interventions |
|
Comparador de Placebo: : Sham PEMF Treatment Patients with inflammatory KOA receive sham PEMF treatment (no effective elect
Sham Pulsed Electromagnetic Field (PEMF) Treatments treatment (matching device without active electromagnetic field) administered twice a week for 8 weeks |
Matching device without active electromagnetic field) administered twice a week for 8 weeks |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Feasibility outcome：adherence
Prazo: 3 months after treatment
|
Adherence will be calculated as the actual number of completed exercise days relative to the prescribed total. |
3 months after treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Serum Levels of Inflammatory Markers and Adipokines
Prazo: Baseline; 3 months after treatment
|
The serum concentrations of the following biomarker: Interleukin-6 (picograms per milliliter, pg/mL). |
Baseline; 3 months after treatment
|
|
Western Ontario and McMaster Universities (WOMAC) pain score
Prazo: Baseline; 3 months after treatment
|
The primary outcome will be the Western Ontario and McMaster Universities (WOMAC) pain score. This scale consists of 5 questions assessing knee joint pain, each scored on a 5-point Likert scale (0 = no pain, 4 = extreme pain). The total score of the pain subscale ranges from 0 to 20, with higher scores indicating a more severe degree of pain. |
Baseline; 3 months after treatment
|
|
Measurement of biomarkers on MRI images of the knee
Prazo: Baseline; 3 months after treatment
|
Cartilage defects (grades 0-4). A higher score indicates more severe pathology. |
Baseline; 3 months after treatment
|
|
Ultrousound measurement
Prazo: Baseline, 1and 3 months after treatment
|
The severity of the following pathologies will be assessed via ultrasonography using semi-quantitative scoring systems: Synovitis(0-3), Osteophytes(0-3), Cartilage damage(0-3). A higher score indicates more severe pathology. |
Baseline, 1and 3 months after treatment
|
|
Six-Minute Walk Distance
Prazo: Baseline;3 months after treatment
|
The total distance walked during the Six-Minute Walk Test, measured in meters (m). |
Baseline;3 months after treatment
|
|
30-Second Chair Stand Test Repetitions
Prazo: Baseline; 3 months after treatment]
|
The maximum number of repetitions of rising fully from a standard-height chair without using arms, sitting back down, and fully rising again, completed within 30 seconds. |
Baseline; 3 months after treatment]
|
|
Timed Up and Go Test Time
Prazo: Baseline; 3 months after treatment
|
The time required to complete the Timed Up and Go Test (rising from a chair, walking 3 meters, turning around, walking back, and sitting down), measured in seconds (s). |
Baseline; 3 months after treatment
|
|
12-Item Short Form Health Survey Score
Prazo: Baseline; 3 months after treatment
|
Assesses overall health-related quality of life. This scale comprises 12 items, which are aggregated into summary scores for physical and mental health. The scores are transformed to a range of 0 to 100, with higher scores indicating better health status. |
Baseline; 3 months after treatment
|
|
Patient Health Questionnaire-9 (PHQ-9) Score
Prazo: Baseline; 3 months after treatment
|
Assesses the severity of depressive symptoms. This scale consists of 9 items, each scored from 0 to 3. The total score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms. |
Baseline; 3 months after treatment
|
|
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score
Prazo: Baseline; 3 months after treatment
|
Assesses the severity of knee stiffness. This subscale contains 2 items, each rated on a 5-point Likert scale (0 = none, 4 = extreme). The total subscale score ranges from 0 to 8, with higher scores indicating worse stiffness. |
Baseline; 3 months after treatment
|
|
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score
Prazo: Baseline; 3 months after treatment
|
Assesses knee-related difficulty in performing daily activities. This subscale contains 17 items, each rated on a 5-point Likert scale (0 = none, 4 = extreme). The total subscale score ranges from 0 to 68, with higher scores indicating worse physical function. |
Baseline; 3 months after treatment
|
|
Serum Levels of Interleukin-6
Prazo: Baseline; 3 months after treatment
|
The serum concentrations of the following biomarkers will be measured: Interleukin-6 (picograms per milliliter, pg/mL) |
Baseline; 3 months after treatment
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- HESEARS20231113002
- 12231596 (Número de outro subsídio/financiamento: Health and Medical Research Fund)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .